Navigation Links
PharmAthene Reports Year-End 2012 Financial And Operational Results
Date:3/13/2013

ANNAPOLIS, Md., March 13, 2013 /PRNewswire/ --

Year-End 2012 Highlights

  • Received favorable final order and judgment from Delaware Chancery Court against SIGA Technologies
  • Accelerated funding for bioscavenger program under Department of Defense contract
  • Strengthened financial position and secured $7.5 million credit facility
  • Achieved 70% year-over-year reduction in operating cash usage
  • PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the year ended December 31, 2012.

    "During the year, the Delaware Court of Chancery issued its final order and judgment awarding PharmAthene a significant economic interest in SIGA's smallpox antiviral therapeutic, Arestvyr™ (formerly known as ST-246®)," said Eric I. Richman, President and Chief Executive Officer. "This represented a major victory for our Company, which, if upheld by the Delaware Supreme Court, should enable us to accelerate our profitability and generate enhanced value for PharmAthene shareholders near-term. Oral arguments on the appeal were held in Delaware Supreme Court in January 2013 and we look forward to the Court's ruling."

    "We also made important technical progress in our next generation recombinant bioscavenger (rBChE) program and are poised to begin pharmacokinetic and non-clinical efficacy testing in the coming months. In recognition of this progress, last year the Department of Defense exercised its option under our current contract to accelerate funding for the rBChE program," said Mr. Richman. "Regarding our SparVax® anthrax vaccine program, we received notification from the Food and Drug Administration (FDA) that our proposed Phase II clinical study of SparVax® was being placed on clinical hold pending the provision of additional dat
    '/>"/>

    SOURCE PharmAthene, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
    2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
    3. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
    4. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
    5. PharmAthene Reports First Quarter 2012 Financial Results
    6. PharmAthene Reports Third Quarter 2012 Financial Results
    7. PharmAthene To Present At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 2013
    8. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
    9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
    (Date:9/30/2014)... Proove Biosciences , the commercial and research leader in ... test built upon research from their published P.A.I.N. Study. ... physicians with an objective way to understand theirs patient’s ... individuals. With this new test, physicians will be able ... that will affect their pain tolerance. , The P.A.I.N. ...
    (Date:9/30/2014)... 2014 Fast, semi-automatic creation ... in documents ChemAxon , a ... services for life science research, launches ChemCurator, an ... structures from documents. Markush structures are ... generating and understanding Markush structures is a difficult ...
    (Date:9/30/2014)... 30, 2014 BioHealth Innovation, Inc. ... biohealth innovations and increasing access to early-stage funding in ... venture capitalist, Tania Fernandez , Ph.D., has joined ... will be a member of the management team for ... to $50 million in seed and early-stage equity investments ...
    Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
    ... convertible notes, and extended the maturity to 2011 on an additional $23.25 ... ... Cell Therapeutics, Inc.,("CTI" or the "Company") (Nasdaq and MTAX: CTIC) today announced ... "New Notes") due 2011 and 5,459,574 shares of its common stock,no par ...
    ... Biosciences,Inc. (Nasdaq: NBIX ) announced today that the ... Administration (FDA) indicating,that the New Drug Application (NDA) for ... of insomnia is approvable pending additional clinical and,preclinical data., ... action letter from the FDA,stating that indiplon 5 mg ...
    ... Company Mails Letter to Shareholders, MONTVALE, N.J., ... today announced that Glass Lewis & Co., one ... that Datascope,shareholders re-elect the Board,s nominees -- James ... Company,s Annual Meeting of Shareholders on,Thursday, December 20, ...
    Cached Biology Technology:Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 2Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 3Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 2Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 3Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 2Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 3Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 4Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 5Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 6Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 7
    (Date:9/30/2014)... engineers, led by Clemson University associate professor Brian ... from the U.S. Department of Energy,s Experimental Program ... positive impact on South Carolina in the advancement ... , "Understanding the scientific and engineering needs for ... nuclear technologies is imperative if South Carolina is ...
    (Date:9/30/2014)... DURHAM, N.C. -- Pollution in urban and farm runoff ... a new study finds. , The study, published ... shows that nitrogen in the runoff ends up in ... tumors on the animals, eyes, flippers and internal organs. ... and the National Oceanic and Atmospheric Administration (NOAA) conducted ...
    (Date:9/30/2014)... release is available in German . ... their behavioural response to risky situations such as exposure ... Ornithology now found in a long-term study on different ... both metabolic rate and ambient temperature. High metabolic rates ... as in these scenarios birds were more likely to ...
    Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Risky metabolism 2
    ... Research on Aging (Novato, CA) and Biotica Technology Ltd. ... polyketides in diseases of aging. Building on observations that ... Kennedy; Nature 2009), the collaborators will evaluate ... of age-related disease models to identify novel therapeutics. ...
    ... no crime. Consider that some strains of algae ... the less harmful varieties suck oxygen out of water, ... Recent algal blooms in the Great Lakes, for instance, ... Andr Hudson and colleagues have figured out how to ...
    ... Cornell University researchers may have solved a 100-year puzzle: ... that therapies to treat Alzheimer,s disease, multiple sclerosis and cancers ... Journal of Neuroscience , Sept. 14, 2011.) , The ... can modulate the entry of large molecules into the brain. ...
    Cached Biology News:Buck Institute and Biotica to investigate polyketides in extension of healthy lifespan 2Outsmarting algae -- RIT scientist finds the turn-off switch 2Breaching the blood-brain barrier 2
    ...
    ... XT is undoubtedly the most complete and ... concept of layers and subsets makes it ... for different data outputs, for example Cy3 ... as well as different subsets of genes ...
    ...
    ...
    Biology Products: